{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Type+II+Diabetes+Mellitus&page=51",
    "query": {
      "condition": "Type II Diabetes Mellitus",
      "page": 51
    },
    "page_size": 10
  },
  "pagination": {
    "page": 51,
    "page_size": 10,
    "total_count": 3594,
    "total_pages": 360,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Type+II+Diabetes+Mellitus&page=52&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Type+II+Diabetes+Mellitus&page=50&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-22T12:18:17.193Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02558296",
      "title": "Bexagliflozin Efficacy and Safety Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Bexagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Theracos",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 1700,
      "start_date": "2015-10",
      "completion_date": "2019-10-23",
      "has_results": true,
      "last_update_posted_date": "2021-07-14",
      "last_synced_at": "2026-11-22T12:18:17.193Z",
      "location_count": 66,
      "location_summary": "Gilbert, Arizona • Little Rock, Arkansas • Azusa, California + 57 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Azusa",
          "state": "California"
        },
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02558296"
    },
    {
      "nct_id": "NCT04034524",
      "title": "Cardiovascular Outcomes and HbA1c Among Patients With Type 2 Diabetes Newly Initiating GLP1RAs vs Basal Insulin",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "GLP-1 receptor agonist",
          "type": "DRUG"
        },
        {
          "name": "Insulin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20000,
      "start_date": "2019-05-01",
      "completion_date": "2020-12-31",
      "has_results": false,
      "last_update_posted_date": "2020-07-09",
      "last_synced_at": "2026-11-22T12:18:17.193Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04034524"
    },
    {
      "nct_id": "NCT04914559",
      "title": "Glucose Response in Persons with Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Oral nutrition supplement - control",
          "type": "OTHER"
        },
        {
          "name": "Oral nutrition supplement - test",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Société des Produits Nestlé (SPN)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "20 Years to 75 Years"
      },
      "enrollment_count": 16,
      "start_date": "2021-05-17",
      "completion_date": "2021-06-30",
      "has_results": false,
      "last_update_posted_date": "2024-10-21",
      "last_synced_at": "2026-11-22T12:18:17.193Z",
      "location_count": 1,
      "location_summary": "Tustin, California",
      "locations": [
        {
          "city": "Tustin",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04914559"
    },
    {
      "nct_id": "NCT01413542",
      "title": "Pharmacogenetics of Ace Inhibitor-Associated Angioedema",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hypertension",
        "Diabetes Type 2"
      ],
      "interventions": [
        {
          "name": "Sitagliptin (DPP4 inhibitor)",
          "type": "DRUG"
        },
        {
          "name": "Substance P,",
          "type": "DRUG"
        },
        {
          "name": "bradykinin",
          "type": "DRUG"
        },
        {
          "name": "enalaprilat (ACE inhibitor)",
          "type": "DRUG"
        },
        {
          "name": "Glucagon-like peptide 1",
          "type": "DRUG"
        },
        {
          "name": "brain natriuretic peptide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 44,
      "start_date": "2011-11",
      "completion_date": "2014-07",
      "has_results": true,
      "last_update_posted_date": "2015-11-04",
      "last_synced_at": "2026-11-22T12:18:17.193Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01413542"
    },
    {
      "nct_id": "NCT00690066",
      "title": "PROCHYMAL® (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus",
        "Type 1 Diabetes",
        "Diabetes Mellitus, Insulin-Dependent",
        "Juvenile Diabetes"
      ],
      "interventions": [
        {
          "name": "PROCHYMAL®",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mesoblast, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "12 Years to 35 Years"
      },
      "enrollment_count": 63,
      "start_date": "2008-06-11",
      "completion_date": "2011-12-19",
      "has_results": false,
      "last_update_posted_date": "2026-03-11",
      "last_synced_at": "2026-11-22T12:18:17.193Z",
      "location_count": 20,
      "location_summary": "Birmingham, Alabama • La Jolla, California • Stanford, California + 17 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00690066"
    },
    {
      "nct_id": "NCT00240383",
      "title": "Dose Ranging Study With LT, Monotherapy, PPAR",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus II"
      ],
      "interventions": [
        {
          "name": "Muraglitazar",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 1260,
      "start_date": "2002-05",
      "completion_date": "2006-06",
      "has_results": false,
      "last_update_posted_date": "2010-09-14",
      "last_synced_at": "2026-11-22T12:18:17.193Z",
      "location_count": 149,
      "location_summary": "Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 146 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Hot Springs",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00240383"
    },
    {
      "nct_id": "NCT05560386",
      "title": "TEEN HEED: An Adolescent Diabetes Prevention Intervention Incorporating Novel Mobile Health Technologies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Text messaging",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Virtual workshop",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Icahn School of Medicine at Mount Sinai",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "19 Years",
        "sex": "ALL",
        "summary": "13 Years to 19 Years"
      },
      "enrollment_count": 54,
      "start_date": "2020-08-01",
      "completion_date": "2022-03-31",
      "has_results": true,
      "last_update_posted_date": "2023-12-29",
      "last_synced_at": "2026-11-22T12:18:17.193Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05560386"
    },
    {
      "nct_id": "NCT05166382",
      "title": "Impact of SomaSignal Tests on the Choice of Glucose-lowering Medications",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Type 2 Diabetes",
        "Cardiovascular Diseases"
      ],
      "interventions": [
        {
          "name": "Informed of results from SomaSignal Cardiovascular Risk Test in Type 2 Diabetes (CVD-T2D)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Not informed of results from SomaSignal Cardiovascular Risk Test in Type 2 Diabetes (CVD-T2D)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 350,
      "start_date": "2022-01-01",
      "completion_date": "2024-01-01",
      "has_results": false,
      "last_update_posted_date": "2025-03-20",
      "last_synced_at": "2026-11-22T12:18:17.193Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05166382"
    },
    {
      "nct_id": "NCT02132442",
      "title": "Hepatic Dysfunction, Vitamin D Status, and Glycemic Control in Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes",
        "Nonalcoholic Fatty Liver Disease",
        "Vitamin D Deficiency"
      ],
      "interventions": [
        {
          "name": "Ergocalciferol, placebo",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "University of Massachusetts, Worcester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "10 Years to 50 Years"
      },
      "enrollment_count": 12,
      "start_date": "2014-03",
      "completion_date": "2016-10",
      "has_results": false,
      "last_update_posted_date": "2017-01-10",
      "last_synced_at": "2026-11-22T12:18:17.193Z",
      "location_count": 1,
      "location_summary": "Worcester, Massachusetts",
      "locations": [
        {
          "city": "Worcester",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02132442"
    },
    {
      "nct_id": "NCT07597161",
      "title": "Neuromodulation for Metabolic Dysfunction",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Spinal Cord Injuries (SCI)",
        "Prediabetes / Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Transcutaneous Spinal Cord Stimulation (tSCS)",
          "type": "DEVICE"
        },
        {
          "name": "Sham transcutaneous spinal cord stimulation (tSCS)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Rahul Sachdeva",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2026-10-20",
      "completion_date": "2030-12",
      "has_results": false,
      "last_update_posted_date": "2026-10-29",
      "last_synced_at": "2026-11-22T12:18:17.193Z",
      "location_count": 1,
      "location_summary": "Lexington, Kentucky",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07597161"
    }
  ]
}